Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.11, Zacks reports. Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock traded up $1.30 on Tuesday, hitting $57.00. 1,478,691 shares of the stock traded hands, compared to its average volume of 667,454. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of 49.57 and a beta of 0.78. Supernus Pharmaceuticals has a 52 week low of $29.16 and a 52 week high of $57.65. The firm has a 50 day simple moving average of $48.25 and a two-hundred day simple moving average of $39.06.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. TD Cowen increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target on the stock. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Finally, Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $63.25.

Insider Activity

In other news, CEO Jack A. Khattar sold 59,900 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. This trade represents a 4.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares in the company, valued at $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 362,741 shares of company stock worth $16,390,592 in the last three months. Company insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently bought and sold shares of SUPN. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $51,000. Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $55,000. Osaic Holdings Inc. grew its stake in Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,328 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Supernus Pharmaceuticals by 255.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company’s stock valued at $134,000 after acquiring an additional 3,051 shares in the last quarter. Finally, Creative Planning purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $242,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.